[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 15, 2000

Sources of Bias in the Economic Analysis of New Drugs

Author Affiliations
 

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(11):1423-1424. doi:10.1001/jama.283.11.1421

To the Editor: The article by Mr Friedberg and colleagues1 includes a statement that the sponsor had a contractual right to review and comment on manuscripts and abstracts prior to submission. However, there is no indication of whether such review was made, whether any comments were offered and, if so, whether they influenced the final manuscript. Disclosure should extend beyond the information that a review is possible and include the facts concerning the review, if one took place, and the influence, if any, that the review had on the manuscript. A separate question is whether investigators should sign contracts that allow sponsors the right to review and comment on data prior to peer review for publication.

First Page Preview View Large
First page PDF preview
First page PDF preview
×